Drugs / Ribaxamase
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04363242 | Apr 2020 → Jul 2023 | carcinoma | Synermore Biologics Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02391727 | May 2015 → Oct 2018 | colorectal cancer, head and neck cancer | Synermore Biologics Co., Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02473640 | Jun 2015 → Apr 2016 | — | Theriva Biologics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02419001 | Mar → Sep 2015 | — | Theriva Biologics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02563106 | Oct 2015 → Nov 2016 | Clostridium difficile colitis, Clostridium infectious disease | Theriva Biologics, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04692181 Comparator | Feb 2021 → Sep 2029 expected | acute graft versus host disease | Theriva Biologics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ribaxamase | “The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies.” PMID 28052855 ↗ Feb 20172“Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients” PMID 30885591 ↗ Mar 2019 “SYN-004, Ribaxamase or Placebo” NCT04692181 ↗ |
| Known as | Ribaxamasa | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989985 ↗ |
| Known as | SYN-004 | “Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg” NCT02419001 ↗ |
| Action | Inhibit | “SYN004 might also inhibit cancer cells” NCT02391727 ↗ |
| Modality | Monoclonal antibody | “a monoclonal antibody that binds to the EGF receptor on cancer cells” NCT02391727 ↗ |
| Route | Intravenous | “single IV loading dose of SYN004” NCT02391727 ↗ |
| Target | EGFR | “binds to the EGF receptor on cancer cells” NCT02391727 ↗ |